Skip to main content
Erschienen in: International Journal of Hematology 5/2014

01.11.2014 | Original Article

Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms

verfasst von: Jarmila Kissova, Alena Bulikova, Petra Ovesna, Ludmila Bourkova, Miroslav Penka

Erschienen in: International Journal of Hematology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

BCR/ABL-negative myeloproliferative neoplasms (MPNs) are considered to be acquired thrombophilic conditions. Persistently enhanced platelet activation has been described in polycythaemia vera and essential thrombocythaemia (ET), and shown to contribute to a higher risk of arterial and venous thrombotic complications. Recent studies have shown that mean platelet volume (MPV) and immature platelet fraction (IPF) can serve as useful markers of platelet activation and increased risk of thrombosis. The aim of the present study was to investigate the relationship between these parameters and thrombotic events in BCR/ABL-negative MPN. MPV values in patients with BCR/ABL-negative MPN were significantly higher than MPV values of healthy individuals (P < 0.001). No significant difference in MPV or IPF was observed between groups of patients with and without thrombotic complications (P = 0.441; P = 0.110); the difference in IPF values was close to the significance level for patients with ET (P = 0.073). Higher values of IPF were more frequently detected in patients with JAK2 V617F positivity (P = 0.030). These patients had higher MPV more frequently than others, and this difference was close to the significance level (P = 0.056). Further studies should validate the use of platelet parameters to identify patients at high risk.
Literatur
1.
Zurück zum Zitat Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, Mazzucconi MG, Rodeghiero F, Tura S. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89:215–32.PubMed Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, Mazzucconi MG, Rodeghiero F, Tura S. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89:215–32.PubMed
2.
Zurück zum Zitat Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Rev. 2001;15:121–31.PubMedCrossRef Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Rev. 2001;15:121–31.PubMedCrossRef
3.
Zurück zum Zitat Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117:755–61.PubMedCrossRef Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117:755–61.PubMedCrossRef
4.
Zurück zum Zitat Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224–32.PubMedCrossRef Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224–32.PubMedCrossRef
5.
Zurück zum Zitat Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, Van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR. United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33–45.PubMedCrossRef Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, Van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR. United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33–45.PubMedCrossRef
6.
Zurück zum Zitat Elliot MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128:275–90.CrossRef Elliot MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128:275–90.CrossRef
7.
Zurück zum Zitat Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, Manarini S, Finazzi G, Cerletti C, Barbui T. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96:4261–6.PubMed Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, Manarini S, Finazzi G, Cerletti C, Barbui T. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96:4261–6.PubMed
8.
Zurück zum Zitat Arellano RE, Alvarez LA, Reverter JC, Colomer D, Villamor N, Bellosillo B, Cervantes F. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol. 2009;84:102–8.CrossRef Arellano RE, Alvarez LA, Reverter JC, Colomer D, Villamor N, Bellosillo B, Cervantes F. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol. 2009;84:102–8.CrossRef
9.
Zurück zum Zitat Falanga A, Russo L, Marchetti M. Mechanisms of thrombogenesis. In: Barbui T, Tefferi A, editors. Myeloproliferative neoplasms. Springer- Verlag: Berlin Heidelberg; 2012. p. 57–67.CrossRef Falanga A, Russo L, Marchetti M. Mechanisms of thrombogenesis. In: Barbui T, Tefferi A, editors. Myeloproliferative neoplasms. Springer- Verlag: Berlin Heidelberg; 2012. p. 57–67.CrossRef
10.
Zurück zum Zitat Harrison CN (2005) Platelets and thrombosis in myeloproliferative diseases. Hematology Am Soc Hematol Educ Program 409–15. Harrison CN (2005) Platelets and thrombosis in myeloproliferative diseases. Hematology Am Soc Hematol Educ Program 409–15.
11.
Zurück zum Zitat Michiels JJ, Berneman Z, Van Bockstaele D, Van der Planken M, De RH, Schroyens W. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost. 2006;32:174–207.PubMedCrossRef Michiels JJ, Berneman Z, Van Bockstaele D, Van der Planken M, De RH, Schroyens W. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost. 2006;32:174–207.PubMedCrossRef
12.
Zurück zum Zitat Arellano RE, Alvarez LA, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006;91:169–75. Arellano RE, Alvarez LA, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006;91:169–75.
13.
Zurück zum Zitat Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005;33:523–30.PubMedCrossRef Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005;33:523–30.PubMedCrossRef
14.
Zurück zum Zitat Jensen MK, Nully BP, Lund BV, Nielsen OJ, Hasselbach HC. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol. 2000;110:116–24.PubMedCrossRef Jensen MK, Nully BP, Lund BV, Nielsen OJ, Hasselbach HC. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol. 2000;110:116–24.PubMedCrossRef
15.
Zurück zum Zitat Kamath S, Blann AD, Lip GY. Platelet activation: assessment and quantification. Eur Heart J. 2001;22:1561–71.PubMedCrossRef Kamath S, Blann AD, Lip GY. Platelet activation: assessment and quantification. Eur Heart J. 2001;22:1561–71.PubMedCrossRef
16.
Zurück zum Zitat Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis. 1996;7:157–61.PubMedCrossRef Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis. 1996;7:157–61.PubMedCrossRef
17.
Zurück zum Zitat Slavka G, Perkmann T, Haslacher H, Greisenegger S, Marsik C, Wagner OF, Endler G. Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease. Arterioscler Thromb Vasc Biol. 2001;31:1215–8.CrossRef Slavka G, Perkmann T, Haslacher H, Greisenegger S, Marsik C, Wagner OF, Endler G. Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease. Arterioscler Thromb Vasc Biol. 2001;31:1215–8.CrossRef
18.
Zurück zum Zitat Berger JS, Eraso LH, Xie D, Sha D, Mohler ER. Mean platelet volume and prevalence of peripheral artery disease, the National Health and Nutrition Examination Survey, 1999-2004. Atherosclerosis. 2010;213:586–91.PubMedCentralPubMedCrossRef Berger JS, Eraso LH, Xie D, Sha D, Mohler ER. Mean platelet volume and prevalence of peripheral artery disease, the National Health and Nutrition Examination Survey, 1999-2004. Atherosclerosis. 2010;213:586–91.PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, Mohler ER, Reilly MP, Berger JS. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. Thromb Heamost. 2010;8:148–56.CrossRef Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, Mohler ER, Reilly MP, Berger JS. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. Thromb Heamost. 2010;8:148–56.CrossRef
20.
Zurück zum Zitat Endler G, Klimesch A, Sunder PH, Schillinger M, Exner M, Mannhalter C, Jordanova N, Christ G, Thalhammer R, Huber K, Sunder PR. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol. 2002;117:399–404.PubMedCrossRef Endler G, Klimesch A, Sunder PH, Schillinger M, Exner M, Mannhalter C, Jordanova N, Christ G, Thalhammer R, Huber K, Sunder PR. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol. 2002;117:399–404.PubMedCrossRef
21.
Zurück zum Zitat Bath P, Algert C, Chapman N, Neal B. Progress Collaborative Group: association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke. 2004;5:622–6.CrossRef Bath P, Algert C, Chapman N, Neal B. Progress Collaborative Group: association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke. 2004;5:622–6.CrossRef
22.
Zurück zum Zitat Braekkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Størmer J, Hansen JB. Mean platelet volume is a risk factor for venous thromboembolism: the Tromsø Study, Tromsø, Norway. J Thromb Haemost. 2010;8:157–62.PubMedCrossRef Braekkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Størmer J, Hansen JB. Mean platelet volume is a risk factor for venous thromboembolism: the Tromsø Study, Tromsø, Norway. J Thromb Haemost. 2010;8:157–62.PubMedCrossRef
23.
Zurück zum Zitat Ingram M, Coopersmith A. Reticulated platelets following acute blood loss. Br J Haematol. 1969;7:225–9.CrossRef Ingram M, Coopersmith A. Reticulated platelets following acute blood loss. Br J Haematol. 1969;7:225–9.CrossRef
24.
Zurück zum Zitat Cesari F, Marcucci R, Caporale R, Paniccia R, Romano E, Gensini GF, Abbate R, Gori AM. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost. 2008;99:930–5.PubMed Cesari F, Marcucci R, Caporale R, Paniccia R, Romano E, Gensini GF, Abbate R, Gori AM. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost. 2008;99:930–5.PubMed
25.
Zurück zum Zitat Cesari F, Marcucci R, Gori AM, Caporale R, Fanelli A, Casola G, Balzi D, Barchielli A, Valente S, Giglioli C, Gensini GF, Abbate R. Reticulated platelets predict cardiovascular death in acute coronary syndrome patients. Insights from the AMI-Florence 2 Study. Thromb Haemost. 2013;109:846–53.PubMedCrossRef Cesari F, Marcucci R, Gori AM, Caporale R, Fanelli A, Casola G, Balzi D, Barchielli A, Valente S, Giglioli C, Gensini GF, Abbate R. Reticulated platelets predict cardiovascular death in acute coronary syndrome patients. Insights from the AMI-Florence 2 Study. Thromb Haemost. 2013;109:846–53.PubMedCrossRef
26.
Zurück zum Zitat Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost. 2009;101:151–6.PubMed Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost. 2009;101:151–6.PubMed
27.
Zurück zum Zitat Nakamura T, Uchiyama S, Yamazaki M, Okubo K, Takakuwa Y, Iwata M. Flow cytometric analysis of reticulated platelets in patients with ischemic stroke. Thromb Res. 2002;106:171–7.PubMedCrossRef Nakamura T, Uchiyama S, Yamazaki M, Okubo K, Takakuwa Y, Iwata M. Flow cytometric analysis of reticulated platelets in patients with ischemic stroke. Thromb Res. 2002;106:171–7.PubMedCrossRef
28.
Zurück zum Zitat Würtz M, Grove EL, Wulff LN, Kaltoft AK, Tilsted HH, Jensen LO, Hvas AM, Kristensen SD. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. JACC Cardiovasc Interv. 2010;3:828–35.PubMedCrossRef Würtz M, Grove EL, Wulff LN, Kaltoft AK, Tilsted HH, Jensen LO, Hvas AM, Kristensen SD. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. JACC Cardiovasc Interv. 2010;3:828–35.PubMedCrossRef
29.
Zurück zum Zitat Biggs C, Kunka S, Hart D, Oguni S, Machin SJ. Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia. Br J Haematol. 2004;126:93–9.CrossRef Biggs C, Kunka S, Hart D, Oguni S, Machin SJ. Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia. Br J Haematol. 2004;126:93–9.CrossRef
30.
Zurück zum Zitat Falanga A, Marchetti M (2012) Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program p. 571–81. Falanga A, Marchetti M (2012) Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program p. 571–81.
31.
Zurück zum Zitat Diquattro M, Gagliano F, Calabró GM, Tammasi M, Scott CS, Mancuso G, Palma B, Menozzi I. Relationships between platelet counts, platelet volumes and reticulated platelets in patients with ITP: evidence for significant platelet count inaccuracies with conventional instrument methods. Int J Lab Hematol. 2009;31:199–206.PubMedCrossRef Diquattro M, Gagliano F, Calabró GM, Tammasi M, Scott CS, Mancuso G, Palma B, Menozzi I. Relationships between platelet counts, platelet volumes and reticulated platelets in patients with ITP: evidence for significant platelet count inaccuracies with conventional instrument methods. Int J Lab Hematol. 2009;31:199–206.PubMedCrossRef
32.
Zurück zum Zitat Landolfi R, Ciabattoni G, Patrignani P, Castellana MA, Pogliani E, Bizzi B, Patrono C. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin- suppressible platelet activation in vivo. Blood. 1992;80:1965–71.PubMed Landolfi R, Ciabattoni G, Patrignani P, Castellana MA, Pogliani E, Bizzi B, Patrono C. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin- suppressible platelet activation in vivo. Blood. 1992;80:1965–71.PubMed
33.
Zurück zum Zitat Arellano RE, Alvaréz LA, Reverter JC, Vilamor N, Jou JM, Cervantes F. Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia. Platelets. 2012;23:336–43.CrossRef Arellano RE, Alvaréz LA, Reverter JC, Vilamor N, Jou JM, Cervantes F. Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia. Platelets. 2012;23:336–43.CrossRef
34.
Zurück zum Zitat Panova NM, Marchetti M, Buoro S, Russo L, Leuzzi A, Finazzi G, Rambaldi A, Ottomano C, Ten CH, Falanga A. JAK2 V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood. 2011;118:2599–601.CrossRef Panova NM, Marchetti M, Buoro S, Russo L, Leuzzi A, Finazzi G, Rambaldi A, Ottomano C, Ten CH, Falanga A. JAK2 V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood. 2011;118:2599–601.CrossRef
35.
Zurück zum Zitat Thompson CB, Jakubowski JA, Quinn PG, Deykin D, Valeri CR. Platelet size and age determine platelet function independently. Blood. 1984;63:1372–5.PubMed Thompson CB, Jakubowski JA, Quinn PG, Deykin D, Valeri CR. Platelet size and age determine platelet function independently. Blood. 1984;63:1372–5.PubMed
36.
Zurück zum Zitat Bessman JD, Williams LJ, Gilmer PR Jr. Mean platelet volume. The inverse relation of platelet size and count in normal subjects, and an artifact of other particles. Am J Clin Pathol. 1981;76:289–93.PubMed Bessman JD, Williams LJ, Gilmer PR Jr. Mean platelet volume. The inverse relation of platelet size and count in normal subjects, and an artifact of other particles. Am J Clin Pathol. 1981;76:289–93.PubMed
37.
Zurück zum Zitat Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Vougarelis M. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res. 2009;33:67–73.PubMedCrossRef Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Vougarelis M. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res. 2009;33:67–73.PubMedCrossRef
38.
Zurück zum Zitat Hobbs CM, Manning H, Bennett C, Vasquez L, Severin S, Brain L, Mazharian A, Guerrero JA, Li J, Soranzo N, Green AR, Watson SP, Ghevaer C. JAK2 V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood. 2013;122:3787–97.PubMedCentralPubMedCrossRef Hobbs CM, Manning H, Bennett C, Vasquez L, Severin S, Brain L, Mazharian A, Guerrero JA, Li J, Soranzo N, Green AR, Watson SP, Ghevaer C. JAK2 V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood. 2013;122:3787–97.PubMedCentralPubMedCrossRef
39.
Zurück zum Zitat Martin J. The relationship between megakaryocyte ploidy and platelet volume. Blood Cells. 1989;15:108–21.PubMed Martin J. The relationship between megakaryocyte ploidy and platelet volume. Blood Cells. 1989;15:108–21.PubMed
Metadaten
Titel
Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms
verfasst von
Jarmila Kissova
Alena Bulikova
Petra Ovesna
Ludmila Bourkova
Miroslav Penka
Publikationsdatum
01.11.2014
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 5/2014
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-014-1673-0

Weitere Artikel der Ausgabe 5/2014

International Journal of Hematology 5/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.